Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors [PDF]
Therapeutic Advances in Medical Oncology, 2022 Background: Combinatorial inhibition of epidermal growth factor receptor (EGFR) and BRAF shows remarkable clinical benefits in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Ting Xu +9 more
doaj +2 more sources
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated [PDF]
Journal of Translational Medicine, 2020 Background Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation.
Muna Al Hashmi +16 more
doaj +5 more sources
Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma [PDF]
Melanoma Management, 2018 Aim: Neoadjuvant treatment of locally advanced disease with BRAF inhibitors is expected to increase the likelihood of a R0 resection. We present six patients with stage III unresectable melanoma, neoadjuvantly treated with BRAF inhibitors.
Marloes Faut +5 more
doaj +4 more sources
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma [PDF]
, 2015 Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from the treatment with BRAF inhibitors alone or in combination with MEK inhibitors.
Ascierto, Paolo Antonio +16 more
core +16 more sources
Frontiers in Oncology, 2021 BackgroundThe combination of BRAF and MEK inhibitors represents the standard of care treatment for patients with metastatic BRAF-mutated melanoma, notwithstanding the high frequency of emergent resistance.
Anna Stagno +6 more
doaj +1 more source
Molecular Therapy: Oncolytics, 2020 BRAF and MEK inhibitors significantly prolong progression-free survival in patients with BRAF mutant melanoma. However, most patients quickly develop drug resistance.
Kun Zhao +4 more
doaj +1 more source
CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma
Genomics, Proteomics & Bioinformatics, 2020 BRAF is a serine/threonine kinase that harbors activating mutations in ∼7% of human malignancies and ∼60% of melanomas. Despite initial clinical responses to BRAF inhibitors, patients frequently develop drug resistance.
Ziyi Li +16 more
doaj +1 more source
Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma [PDF]
Zhongguo aizheng zazhi, 2022 Most melanomas have BRAF V600E/K mutations, making V600 an important target for precision treatment of melanoma, and it can often be blocked by a combination of BRAF inhibitors and MEK inhibitors.
JIANG Jianyun, YING Hongmei
doaj +1 more source
CRAF R391W is a melanoma driver oncogene. [PDF]
, 2016 Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known.
Atefi, Mohammad +11 more
core +7 more sources
Encorafenib plus cetuximab for the treatment of -mutated metastatic colorectal cancer
Therapeutic Advances in Gastroenterology, 2022 B-type RAF ( BRAF ) -V600E mutations in metastatic colorectal cancer (mCRC) have been described in up to 12% of the patients. This mutation confers a bad prognostic and poor response with standard chemotherapy.
Javier Ros +5 more
doaj +1 more source